• The pullback follows a massive rally that saw shares climb from below $0.30 to over $4.00 as traders chased momentum following FDA 510(k) clearance for MEDIFLY Maggots and regained Nasdaq compliance earlier this week.
  • With no fresh company-specific news or filings on June 18, 2026, today's 7% move appears to be a normal profit-taking phase.